Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066586 · ClinicalTrials.gov registry record · NA
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
A NA study of Breast Cancer, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 12
- Study locations
NCT00066586 is a NA study of Breast Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT00066586, a NA study of Breast Cancer, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 12
- Study locations
Study Summary
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density. PURPOSE: Randomized clinical trial to study the effectiveness of exemestane in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density in postmenopausal women who are at increased risk for breast cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG exemestane
Study Locations (12)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
Ontario
- Margaret and Charles Juravinski Cancer Centre - Hamilton
- Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre - Thunder Bay
- Princess Margaret Hospital - Toronto
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Minnesota
- Mayo Clinic Cancer Center - Rochester
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University - Columbus
Rhode Island
- Memorial Hospital of Rhode Island - Pawtucket
Quebec
- Centre Hospitalier de l'Universite de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2001-08-01 |
| Est. Completion | 2009-02-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066586
The ClinicalTrials.gov registry entry for NCT00066586 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00066586 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT00066586 about?
NCT00066586 is a clinical study titled "Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer". RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen levels and reducing breast density. PURPOSE: Randomized clinical trial to s...
What is the current status of trial NCT00066586?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2001-08-01. Estimated completion is 2009-02-10.
What conditions does trial NCT00066586 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00066586?
The interventions under investigation include: Placebo (DRUG), exemestane (DRUG).
Who is sponsoring clinical trial NCT00066586?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00066586 being conducted?
This trial has 12 study locations across Florida, Massachusetts, Minnesota, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.